133 related articles for article (PubMed ID: 15003357)
1. Helospectin I and II evoke vasodilation in the intact peripheral microcirculation.
Tsueshita T; Onyükusel H; Sethi V; Gandhi S; Rubinstein I
Peptides; 2004 Jan; 25(1):65-9. PubMed ID: 15003357
[TBL] [Abstract][Full Text] [Related]
2. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
[TBL] [Abstract][Full Text] [Related]
3. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
Ashok B; Rubinstein I; Tsueshita T; Onyüksel H
Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
[TBL] [Abstract][Full Text] [Related]
4. Multiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons.
Kamaishi H; Endoh T; Suzuki T
Auton Neurosci; 2004 Mar; 111(1):15-26. PubMed ID: 15109935
[TBL] [Abstract][Full Text] [Related]
5. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
6. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
8. Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1--38).
Tsueshita T; Gandhi S; Onyüksel H; Rubinstein I
J Appl Physiol (1985); 2002 Oct; 93(4):1377-83. PubMed ID: 12235038
[TBL] [Abstract][Full Text] [Related]
9. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
[TBL] [Abstract][Full Text] [Related]
10. Helospectin/helodermin-like peptides in guinea pig lung: distribution and dilatory effects.
Cardell LO; Sundler F; Uddman R
Regul Pept; 1993 Jun; 45(3):435-43. PubMed ID: 8351407
[TBL] [Abstract][Full Text] [Related]
11. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
13. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
Grant S; Lutz EM; McPhaden AR; Wadsworth RM
J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
[TBL] [Abstract][Full Text] [Related]
14. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
16. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
18. Unlike VIP, the VIP-related peptides PACAP, helodermin and helospectin suppress electrically evoked contractions of rat vas deferens.
Grundemar L; Håkanson R
Regul Pept; 1992 Aug; 40(3):331-7. PubMed ID: 1438978
[TBL] [Abstract][Full Text] [Related]
19. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
20. Role of VIP and PACAP in islet function.
Winzell MS; Ahrén B
Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
